What To Do About Caronia
This article was originally published in RPM Report
Executive Summary
While pharmaceutical marketers wait to hear how the government will respond to the Second Circuit’s off-label communication Caronia court ruling, PhRMA is considering ways to take the initiative. On the table: working proactively with FDA to re-frame the rules around off-label promotion.